RxDoctor Payments Data

Ashish Agarwal, MD

Cardiovascular Disease · Robbinsville, NJNPI 1821174483

Payments from drug & device makers

$1,387in general payments, 2019–2025

Across 78 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$236
  • Novartis$213
  • E.r. Squibb & Sons, L.L.C.$168
  • Boston Scientific$135
  • Medtronic$123
  • Amgen$121
  • plus $392 from 11 others

What the payments were for

  • Food & beverage$1,35398%
  • Education$342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,387 in reported general payments places this provider in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$175,447
Medicare patients
1,346
Services billed
3,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban525$671,483
XareltoRivaroxaban151$200,997
EntrestoSacubitril/Valsartan133$170,423
Repatha SureclickEvolocumab106$128,512
MultaqDronedarone Hcl55$95,911
FarxigaDapagliflozin Propanediol74$91,528
Praluent PenAlirocumab56$52,367
Icosapent Ethyl41$19,426
BrilintaTicagrelor24$18,710
VascepaIcosapent Ethyl23$16,124
Rosuvastatin Calcium831$14,755
Metoprolol Succinate807$12,670
Dabigatran EtexilateDabigatran Etexilate Mesylate23$10,129
Valsartan188$7,835
Pitavastatin Calcium11$6,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$671,483525 claims
Johnson & JohnsonXarelto$236$200,997151 claims
NovartisEntresto$213$170,423133 claims
AstraZenecaFarxiga, Brilinta$45$110,23898 claims
Sanofi-aventis U.S. LLCMultaq$45$95,91155 claims
Kowa Pharmaceuticals America, Inc.Bystolic$43$2,89714 claims
Boehringer IngelheimPradaxa$37$2,33912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Robbinsville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →